Patents Represented by Attorney Carlos A. Fisher

Find this attorney in the Justia Lawyer Directory

  • Method for treating cancer with a neurotoxin to improve patient function
    Patent number: 6368605
    Abstract: A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic adrenal medulla, by direct, local administration of a neurotoxin, such as a botulinum toxin.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: April 9, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6369261
    Abstract: Compounds having Formula 2 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: April 9, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Alan T. Johnson, Jayasree Vasudevan, Liming Wang, Roshantha A. Chandraratna
  • Compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6369225
    Abstract: Compounds having Formula 8 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: April 9, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Dehua Huang, Roshantha A. Chandraratna
  • Compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6359135
    Abstract: Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: March 19, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Dehua Huang, Roshantha A. Chandraratna
  • Method for treating Hashimoto's thyroiditis
    Patent number: 6358513
    Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a neurotoxin, such as a botulinum toxin, to the thyroid gland of a patient, thereby reducing an inhibitory effect upon thyroid hormone secretion.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: March 19, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Martin A. Voet, Stephen Donovan
  • Neurotoxin therapy for inner ear disorders
    Patent number: 6358926
    Abstract: Methods for treating otic disorders by local administration of a neurotoxin. A botulinum toxin can be administered to myoclonic middle ear muscles and to inner ear efferent and/or afferent nerves to alleviate otic disorders such as tinnitus, cochlear nerve dysfunction and Meniere's disease.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: March 19, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
    Patent number: 6359181
    Abstract: The present invention provides a novel compound represented by the general formula I; wherein R is H or COR3; R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl; Z is CH2 or O; Y is OH, OCOR3 or ═O; x is 0 or 1; and X is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: March 19, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Extended dynamic range assays
    Patent number: 6350579
    Abstract: A method and compositions for the detection and/or quantification of an analyte through the use of a plurality of labeled probes, with two or more said probes targeted to different regions of said analyte. In specific embodiments, the labels are separately distinguishable, and/or are present at different specific activities on the labels.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: February 26, 2002
    Assignee: Gen-Probe Incorporated
    Inventor: Norman C. Nelson
  • Methods and compositions for drug delivery
    Patent number: 6350780
    Abstract: Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having calcium chelating activity. Examples of calcium chelating agents utilized in the pharmaceutical composition and method of treatment are: and lower alkyl and alkoxyalkyl esters thereof. Also disclosed are methods and compositions for delivering a drug within the cytoplasm of a cell having cell surface acetylcholinesterase or acetylcholinesterase receptors, wherein the compositions comprise an apolar prodrug joined to an acetylcholine ester or psuedoacetylcholine group.
    Type: Grant
    Filed: April 5, 1999
    Date of Patent: February 26, 2002
    Assignee: Allergan Sales, Inc.
    Inventors: Michael E. Garst, Joseph S. Adorante
  • Method for treating a catecholamine secretion
    Patent number: 6350455
    Abstract: A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic adrenal medulla, by direct, local administration of a neurotoxin, such as a botulinum toxin.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: February 26, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Methods for treating diabetes
    Patent number: 6337075
    Abstract: The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into a sympathetic ganglion, thereby reducing an inhibitory effect upon insulin secretion.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: January 8, 2002
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Method for treating hyperparathyroidism
    Patent number: 6328977
    Abstract: A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: December 11, 2001
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Methods of treating pain and other conditions
    Patent number: 6329369
    Abstract: Methods of treating glaucoma or elevated pressure and other diseases with reduced side effects by treating a mammal in need thereof an agonist of the alpha 2B or alpha 2B/2C adrenergic receptor(s). Also described are compounds having such selective agonist activity.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: December 11, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Ken Chow, Daniel W. Gil, James A. Burke, Dale A. Harcourt, Michael E. Garst, Larry A. Wheeler, Stephen A. Munk
  • Conformationally rigid bicyclic and adamantane derivatives useful as &agr;2-adrenergic blocking agents
    Patent number: 6319935
    Abstract: A compound of formula I in which: ring A is one of the five alternative multi-cyclic rings as shown wherein a dotted line adjacent to a bond indicates that a single bond or a double bond may be present at that position; X is nitrogen, oxygen or sulfur; R is hydrogen, lower straight or branched chain alkyl of 1 to 6 carbon atoms, or lower straight or branched chain alkenyl of 2 to 6 carbon atoms, a cycloaliphatic ring of 3 to 6 carbon atoms, phenyl optionally mono- or di-substituted with hydroxy, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 2 carbon atoms, or methylenedioxyphenyl; or a stereoisomer, or a pharmaceutically acceptable salt thereof. These compounds have &agr;2 receptor blocking activity and hence find use in the treatment or palliation of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity.
    Type: Grant
    Filed: April 4, 2000
    Date of Patent: November 20, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Stephen A. Munk, Michael E. Garst, James A. Burke
  • Method for treating hypercalcemia
    Patent number: 6319506
    Abstract: A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: November 20, 2001
    Assignee: Allergan, Sales, Inc.
    Inventor: Stephen Donovan
  • Methods and compositions for modulating alpha adrenergic receptor activity
    Patent number: 6313172
    Abstract: Methods and compositions for the treatment of pain using this area derivatives. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: November 6, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Ken Chow, Daniel W. Gil, Wenkui Ken Fang, Michael E. Garst, Larry A. Wheeler
  • Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
    Patent number: 6313107
    Abstract: Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: November 6, 2001
    Assignee: Allergan Sales, Inc.
    Inventors: Jayasree Vasudevan, Alan T. Johnson, Liming Wang, Dehua Huang, Roshantha A. Chandraratna
  • Botulinum toxin implant
    Patent number: 6312708
    Abstract: A controlled release system for multiphasic, in vivo release of therapeutic amounts of botulinum toxin in a human patient over a prolonged period of time. The controlled release system can comprise a plurality of botulinum toxin incorporating polymeric microspheres.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: November 6, 2001
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    Patent number: 6310087
    Abstract: The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I: wherein wavy line attachments indicate either the alpha (&agr;) or beta (&mgr;) configuration; dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1 and —N(R1)2, Y is =O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 30, 2001
    Assignee: Allergan Sales, Inc.
    Inventor: Robert M. Burk
  • Method for treating parkinson's disease with a botulinum toxin
    Patent number: 6306403
    Abstract: Methods for treating a movement disorder by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: October 23, 2001
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan